ArticleJournal of Cancer2026
Radiation-induced SLAMF1 reconfigures the SLAM family receptors landscape in triple-negative breast cancer cells.
Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation therapy is a powerful immunomodulator capable of transforming the tumor microenvironment (TME). Signaling Lymphocytic Activation Molecule Family Member 1 (SLAMF1) is a cell surface receptor involved in various immune functions and cancer progression by regulating interactions with the immune microenvironment. However, the specific role of radiation in modulating the SLAM family within tumor cells remained poorly understood. Ionizing radiation markedly increased the expression of SLAM family, including SLAMF1, and other immune checkpoints in three triple-negative breast cancer (TNBC) cell lines by flow cytometry analysis. Furthermore, dual immunofluorescence staining of breast cancer patient tissues confirmed that SLAMF1 is localized to tumor site independently of immune cells. Interestingly, SLAMF1 overexpression in TNBC cells distinctively reconfigures the expression of SLAMF2 and SLAMF5, both linked to immunosuppressive signaling. These findings suggest a potential mechanism where radiation-induced SLAMF1 influences tumor immunogenicity by remodeling the inhibitory SLAM receptors landscape, potentially rendering tumor cells more susceptible to immune-mediated attack. As the first study to demonstrate endogenous SLAMF1 as a novel radiation-responsive factor in breast cancer, these results provide key insights for developing combined radiotherapy and immunotherapy strategies for TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.